

Sravanti Rangaraju

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10259673/publications.pdf>

Version: 2024-02-01

8
papers

13
citations

2682572
2
h-index

2272923
4
g-index

8
all docs

8
docs citations

8
times ranked

0
citing authors

#	ARTICLE	IF	CITATIONS
1	Safe and Effective Use of Imatinib to Treat Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia During Pregnancy. <i>Journal of Adolescent and Young Adult Oncology</i> , 2022, , .	1.3	2
2	IDH1 inhibitor-induced neutrophilic dermatosis in a patient with acute myeloid leukemia. <i>Cancer Treatment and Research Communications</i> , 2022, 31, 100560.	1.7	2
3	Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2022, , .	2.5	1
4	Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2022, 117, 106844.	0.8	7
5	A phase 1 study of NTX-301, an oral DNMT1 inhibitor, in patients with MDS and AML (trial in progress).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS7077-TPS7077.	1.6	1
6	Survival outcomes of patients with relapsed or refractory acute myeloid leukemia after venetoclax combined with hypomethylating agents.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18808-e18808.	1.6	0
7	Abstract 800: Exploiting the proteasome to overcome RAS and WT1 mutation mediated resistance to FLT-3 inhibition in acute myeloid leukemia. , 2020, , .		0
8	Identification of Beta-Catenin As a Novel Ubiquitin-Regulated Target of Combined Flt ³ /Syk- and Proteasome Inhibitors for Interruption of LSC Signaling in Poor-Risk AML. <i>Blood</i> , 2018, 132, 3949-3949.	1.4	0